Tag: Novavax (NVAX)

The COVID-19 Vaccines’ Developing Firms’ Bizarre Evaluations

Novel Coronavirus Vaccines and Wall Street Vaccines against novel coronavirus are recognized now as the only way to return disrupted human lives back to normal. Vaccines have become the most important topic for Wall Street’s investors and analysts especially at times when the virus demonstrates its capability to continue disrupting human lives on the entire planet. Betting up and down on the firms that are …

Questions & Answers

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2 Inovio (INO) announced the publication of the preclinical study data for its novel coronavirus SARS-CoV-2 DNA vaccine INO-4800 which is demonstrating robust neutralizing antibody and T cell immune responses against COVID-19. The study was published in the peer-reviewed journal Nature Communications titled, "Immunogenicity of a . . . This content is for paid subscribers. Please click here to subscribe …

The Impacting News of the Day

Impacting News from Novavax, CymaBay Therapeutics and Sanofi SA Novavax  The Grant That Rallied the Stock Novavax (NVAX) stock jumped sky-high following the announcement that the firm has been granted up to $384 million by the coalition for Epidemic Preparedness innovation. The grant is to help the advancement in the clinical development of the firm’s SARS-CoV-2 (COVID . . . This content is for paid …
An Evaluation of Biotech Firms Part 4

An Evaluation of Biotech Firms Part 4

A Comprehensive Essay  Part 4 Our fair evaluation approaches of biotechnology and biopharma companies differ depending on the sizes and statuses of the firms. We reiterate our conviction that causing a selloff of development stage biotech stocks at every announcement of quarterly financial results because of lack of income is irrelevant and unfair to the firms and their stockholders. It does not make sense that …

Novavax: A Hand-Picked Vaccine on the Road Towards Human Clinical Trial Against Coronavirus

Novavax Identified an "Ideal" Coronavirus Vaccine Candidate The news from Novavax (NVAX) informs that the firm has identified an "ideal" coronavirus vaccine candidate, NVX-CoV2373, that is a stable, prefusion protein made using Novavax’s proprietary nanoparticle technology. The firm will initiate a first-in-human trial in mid-May. Novavax’s proprietary Matrix-M . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Its All About Coronavirus

Its All About Coronavirus

Coronavirus: The Possible Treatments While Moderna’s (MRNA) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human clinical trials in the next few months. Regeneron (REGN) is one of the most trusted companies. In collaboration with Sanofi (SNY) the companies are on the top of …

Fighting COVID-19. See Also: Stocks Gains Following the Market’s Rebounding

Treating and Preventing COVID-19 Treating COVID-19, Gilead Sciences With regard to treating patients with COVID-19 we believe the most expected product to be used during this virus' outbreak will be Gilead Sciences’ (GILD) product remdesivir. This product has reduced the severity of the coronavirus infection symptoms in animal testing and in a few . . . This content is for paid subscribers. Please click here to …